Eli Lilly and Company (NYSE: LLY) and Verve Therapeutics, Inc. (NASDAQ: VERV) today announced that the tender offer to ...

Eli Lilly and Company (NYSE:LLY) is one of the 13 Best Low Risk High Growth Stocks to Buy. Amid carrying on new studies, the ...

Kiran Musunuru, a University of Pennsylvania cardiologist and leading gene-editing researcher, thinks it’s possible. Musunuru cofounded Verve Therapeutics, a company developing a therapy that uses ...

Despite former President Donald Trump’s threat of a 200% tariff on imported drugs during a cabinet meeting, pharmaceutical investors have shown surprisingly positive sentiment this week. Despite ...

Pharmaceutical giant Eli Lilly delivers strong financial results and has a deep lineup and pipeline. Much smaller Viking Therapeutics boasts several candidates whose progress could jolt its shares.

Eli Lilly is walking through the Gate, inking a deal worth up to $856 million with a biotech aiming to build out a new small ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

The death of a third patient tied to a Sarepta Therapeutics gene therapy this year sent the company’s shares nosediving 36% ...